
Esprint Investigación
Vol. 5 N° Esp.2, Edición Especial 2026 (493-512)
Salud y Ciencias de la Vida
ISSN: 2960-8317
Ana Gabriela Palomo Urrutia
, María Eugenia Lucena de Ustáriz
510
Galván, R., Martín, S., & Almazo, I. (2026). Diagnóstico de diabetes mellitus tipo 1 por el laboratorio
clínico. NPunto, 9(95), 4–27. https://n9.cl/uiemui
Gibb, F., McKnight, J., Clarke, C., & Strachan, M. (2020). Preserved C-peptide secretion is associated
with fewer low-glucose events and lower glucose variability on flash glucose monitoring in
adults with type 1 diabetes. Diabetologia, 63(5), 906–914. https://doi.org/10.1007/s00125-020-
05099-3
Giunta, J., & Grosembacher, L. (2024). Comité de Trasplante. Seguimiento clínico de la funcionalidad
de la célula ß a largo plazo en pacientes con trasplante renopancrático o páncreas aislado. Revista
de la Sociedad Argentina de Diabetes, 58(1, Supl.), 50–52. https://doi.org/10.47196/diab.v58i1Sup.768
Gubitosi-Klug, R., Braffett, B. H., Hitt, S., Arends, V., Uschner, D., Jones, K., Diminick, L., Karger, A.
B., Paterson, A., Roshandel, D., Marcovina, S., Lachin, J., Steffes, M., Palmer, J., & DCCT/EDIC
Research Group. (2021). Residual β cell function in long-term type 1 diabetes associates with
reduced incidence of hypoglycemia. Journal of Clinical Investigation, 131(3), e143011.
https://doi.org/10.1172/JCI143011
Haddaway, N., Page, M., Pritchard, C., & McGuinness, L. (2022). PRISMA2020: An R package and
Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for
optimised digital transparency and Open Synthesis. Campbell Systematic Reviews, 18(2), e1230.
https://doi.org/10.1002/cl2.1230
Iqbal, S., Abu Jayyab, A., Alrashdi, A., Shujauddin, S., Clua-Espuny, J., & Reverté-Villarroya, S. (2024).
The predictive potential of C-peptide in differentiating type 1 diabetes from type 2 diabetes in
an outpatient population in Abu Dhabi. Clinical Therapeutics, 46(9), 696–701.
https://doi.org/10.1016/j.clinthera.2024.07.002
Llanos, I., Maselli, M. del C., & Valdez, S. N. (2025). Péptido C. Estado actual de su medición. Revista
de la Sociedad Argentina de Diabetes, 59(3), 172–175. https://doi.org/10.47196/diab.v59i3.1291
Maddaloni, E., Bolli, G., Frier, B., Little, R., Leslie, R., Pozzilli, P., & Buzzetti, R. (2022). C-peptide
determination in the diagnosis of type of diabetes and its management: A clinical perspective.
Diabetes, Obesity and Metabolism, 24(10), 1912–1926. https://doi.org/10.1111/dom.14785
Muzzio, M., & Meroño, T. (2020). Características y utilidad clínica de la medida de péptido C.
Bioquímica y Patología Clínica, 84(1), 39–48. https://doi.org/10.62073/bypc.v84i1.36
Odyjewska, E., Kupińska, M., Jamiołkowska-Sztabkowska, M., Bossowski, A., & Głowińska-
Olszewska, B. (2025). Residual beta-cell function in children with type 1 diabetes after a partial
remission phase – A possible relation between C-peptide and betatrophin. Frontiers in
Endocrinology, 16, 1602777. https://doi.org/10.3389/fendo.2025.1602777
Page, M.., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., Mulrow, C., Shamseer, L., Tetzlaff, J.
M., Akl, E., Brennan, S., Chou, R., Glanville, J., Grimshaw, J., Hróbjartsson, A., Lalu, M., Li, T.,
Loder, E., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An
updated guideline for reporting systematic reviews. BMJ, 372, n71.
https://doi.org/10.1136/bmj.n71
So, M., Vogrin, S., Waibel, M., Kay, T. W. H., & Wentworth, J. M. (2025). β-cell function derived from
routine clinical measures reports and predicts treatment response to immunotherapy in recent-
onset type 1 diabetes. Diabetes Care, 48(8), 1370–1376. https://doi.org/10.2337/dc25-0565